Antagonism of Stem Cell Factor/c-kit Signaling Attenuates Neonatal Chronic Hypoxia-Induced Pulmonary Vascular Remodeling

Karen C Young1,2,3,*, Eneida Torres1,2, Dorothy Hehre1,2, Shu Wu1,2, Cleide Suguihara1,2, and Joshua M. Hare3,4
1Department of Pediatrics, University of Miami Miller School of Medicine, Miami, Florida, USA
2Batchelor Children’s Research Institute, University of Miami Miller School of Medicine, Miami, Florida, USA
3The Interdisciplinary Stem Cell Institute, University of Miami Miller School of Medicine, Miami, Florida, USA
4Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida

Abstract

Background—Accumulating evidence suggests that c-kit positive cells are present in the remodeled pulmonary vasculature bed of patients with pulmonary hypertension (PH). Whether stem cell factor (SCF)/c-kit regulated pathways potentiate pulmonary vascular remodeling is unknown. Here, we tested the hypothesis that attenuated c-kit signaling would decrease chronic hypoxia-induced pulmonary vascular remodeling by decreasing pulmonary vascular cell mitogenesis.

Methods—Neonatal FVB/NJ mice treated with non-immune IgG (PL), or c-kit neutralizing antibody (ACK2) as well as c-kit mutant mice (WBB6F1- Kit W−/− v/+ ) and their congenic controls, were exposed to normoxia (FiO2=0.21) or hypoxia (FiO2=0.12) for two weeks. Following this exposure, right ventricular systolic pressure (RVSP), right ventricular hypertrophy (RVH), pulmonary vascular cell proliferation and remodeling were evaluated.

Results—As compared to chronically hypoxic controls, c-kit mutant mice had decreased RVSP, RVH, pulmonary vascular remodeling and proliferation. Consistent with these findings, administration of ACK2 to neonatal mice with chronic hypoxia-induced PH decreased RVSP, RVH, pulmonary vascular cell proliferation and remodeling. This attenuation in PH was accompanied by decreased extracellular signal-regulated protein kinase (ERK) 1/2 activation.
**Conclusion**—SCF/c-kit signaling may potentiate chronic hypoxia-induced vascular remodeling by modulating ERK activation. Inhibition of c-kit activity may be a potential strategy to alleviate PH.

**Introduction**

Neonatal chronic hypoxia-induced pulmonary hypertension (PH) is characterized by vascular pruning and profound remodeling of peripheral pulmonary vessels (1). These pulmonary vascular changes mimic those seen in infants with severe bronchopulmonary dysplasia and are a significant cause of morbidity and mortality. Currently, mechanistic pathways remain unclear and there are few efficacious therapies.

CD117 or c-kit, a tyrosine kinase receptor encoded at the W/Kit locus (2) is mainly utilized as a stem cell marker (3, 4). Yet this receptor is also expressed on myocardial tissue, mast cells, dendritic cells, systemic vascular smooth muscle cells, epithelial cells, and fetal pulmonary vascular endothelial cells (2, 5-7). The ligand for c-kit is stem cell factor (SCF). Encoded at the steel locus on murine chromosome 10, SCF is expressed by several cells, including endothelial cells and lung fibroblasts (8). Interestingly, although recent studies have demonstrated increased c-kit cells in the media and adventitia of remodeled pulmonary arterioles, the role of SCF/c-kit signaling in the pathogenesis of PH is unclear (9-11).

It is however known that binding of SCF to c-kit results in dimerization of the receptor, with subsequent activation of its intrinsic tyrosine kinase and phosphorylation of its tyrosine residues (12). These phosphorylated sites are known to function as docking stations for several signal transduction proteins which induce the activation of signaling pathways, believed to be responsible for SCF/c-kit role in cell differentiation, survival and proliferation (13, 14). This latter process is particularly relevant in the context of PH as pulmonary vascular proliferation is one of the main mechanisms postulated to contribute to the pulmonary vascular remodeling evidenced in this disease.

Consistent with this theory, other investigators have suggested that c-kit and SCF play important roles in systemic vascular remodeling. The expression of c-kit and SCF were increased in atherosclerotic vessels (5) and mice with defective c-kit signaling (c-kit mutant mice) had decreased systemic vascular remodeling following injury (14, 15). Moreover, administration of imatinib mesylate (a non-specific c-kit antagonist) improved pulmonary vascular resistance as well as walking distance in idiopathic PH (16).

This present study sought to test the hypothesis that activation of c-kit signaling potentiates neonatal chronic hypoxia-induced pulmonary vascular remodeling by increasing pulmonary vascular cell proliferation. Using a chronic hypoxia in vivo model of neonatal PH, we show that neonatal hypoxic c-kit mutant mice exhibit decreased PH, right ventricular hypertrophy (RVH), pulmonary vascular cell proliferation and remodeling as compared to control hypoxic mice. In addition, we show that antagonism of c-kit attenuated neonatal chronic hypoxia-induced pulmonary vascular proliferation and remodeling. Further questioning to ascertain the mechanisms by which c-kit may participate in chronic hypoxia-induced
pulmonary vascular remodeling revealed that SCF/c-kit signaling increased neonatal pulmonary vascular smooth muscle cell proliferation by augmenting extracellular signal-regulated protein kinase (ERK) 1/2 activation. These findings provide important insight into the involvement of SCF/c-kit signaling in the pathogenesis of PH.

Results

SCF and c-kit expression in remodeled pulmonary arterioles of mice with PH

We first sought to ascertain whether the expression of c-kit and its ligand, SCF were increased in the pulmonary arterioles of neonatal FV/NJ mice with chronic hypoxia-induced PH (Figures 1A–1D). Newborn FVB/NJ mice were exposed to two weeks of normobaric normoxia or hypoxia. Following this exposure, pulmonary arterioles were dissected. There was a significant increase in the protein expression of c-kit (1.5 fold, p< 0.03), SCF (1.5 fold, p<0.001) and phosphorylated c-kit (2 fold, p<0.002) in the pulmonary arterioles of mice with PH (Figures 1A–1C). Immuno-fluorescent staining revealed that c-kit was expressed on pulmonary vascular endothelial, medial and adventitial cells (Figure 1D).

Antagonism of SCF/c-kit signaling attenuates Pulmonary Vascular Remodeling

We next exposed neonatal mice to chronic hypoxia or normoxia from postnatal day 1–14 and then randomly assigned them to receive daily IP injections of a neutralizing c-kit antibody (ACK2) or placebo (PL) from postnatal day 7–14. As compared to normoxia, chronically hypoxic PL mice had a significant increase in right ventricular systolic pressure (RVSP; 15 ± 1 vs. 28 ± 4 mmHg; RA vs. hypoxia-PL; p<0.001), ratio of the weight of right ventricle to the left ventricle + septum (RV/LV +S; 0.3 ± 0.1 vs. 0.5 ± 0.1: RA vs. hypoxia-PL; p<0.001), pulmonary vascular cell remodeling and pulmonary vascular cell proliferation (Figures 2A–2F). In contrast, as compared to hypoxia PL-treated mice, the administration of ACK2 to mice with PH, decreased right ventricular RVSP (28 ± 4 vs. 21 ± 2 mmHg : hypoxia-PL vs. hypoxia-ACK2; p<0.02), RV/LV+S (0.5 ± 0.1 vs. 0.4 ± 0.1: hypoxia-PL vs. hypoxia-ACK2; p<0.01), pulmonary vascular cell remodeling and pulmonary vascular cell proliferation (Figures 2A–2F), suggesting that antagonism of SCF/c-kit signaling can attenuate PH.

Given that neonatal exposure to chronic hypoxia negatively impacts lung alveolarization, we evaluated the effect of ACK2 on lung alveolarization by measuring mean linear intercept (MLI). Normoxic mice which received ACK2 had a trend for worsened alveolarization, evidenced by increased MLI (36±5 vs. 41±5 μm; RA-PL vs RA-ACK2; p<0.06, n=5/group). Surprisingly, hypoxia-ACK2 mice had significantly lower MLI as compared to hypoxia-PL mice (49±3 vs 40±6 μm; hypoxia-PL vs. hypoxia-ACK2; p<0.03), suggesting that SCF/c-kit antagonism may improve alveolarization in neonatal hypoxic mice with PH (Figure 3A–B). This improvement in lung alveolarization was however not accompanied by an increase in lung vascular density (6±3 vs 6±1 vessels/high power field; hypoxia-PL vs. hypoxia-ACK2), Figure 3C.
c-kit Mutant Mice have decreased susceptibility to chronic hypoxia-induced PH

Next, we questioned whether neonatal c-kit mutant mice would have decreased susceptibility to developing chronic hypoxia-induced PH. The c-kit mutant mice utilized in this study have the W-v mutation which is a missense mutation in the kinase domain of the c-kit coding sequence. During normoxia, there was no difference in RVSP, RVH, pulmonary vascular remodeling nor the pulmonary vascular proliferative index between the control and the mutant mice (Figures 4A–4F). Moreover, whilst exposure to chronic hypoxia resulted in a significant increase in RVSP (20 ± 1 vs. 30 ± 5 mmHg: RA control vs. hypoxia control; p<0.001), RV/LV+S, pulmonary vascular cell proliferation and remodeling in the control mice, these changes were significantly attenuated in the c-kit mutant mice (Figures 4A–4F).

SCF/c-kit signaling modulates PASM proliferation by regulating ERK1/2 Activation

Given evidence suggesting that chronic hypoxic exposure may increase extracellular signal-regulated protein kinase (ERK) -mediated signaling and that the latter may be important in hypoxia-induced pulmonary vascular cell proliferation (17, 18), we questioned whether SCF/c-kit regulates pulmonary vascular cell proliferation by activating the ERK1/2 signaling pathway. As compared to normoxic mice, control mice exposed to chronic hypoxia had significantly increased expression of p-ERK1/2 (Figure 5A). In contrast, p-ERK1/2 expression was unchanged in chronically hypoxic c-kit mutant mice (Figure 5A). Similarly, whilst PL-treated hypoxic neonatal mice had an increase in ERK1/2 activation, administration of ACK2 to hypoxic mice decreased ERK1/2 activation (Figure 5B). These findings suggest that c-kit may regulate pulmonary vascular cell proliferation by regulating ERK signaling.

SCF Increases PASM Cell Proliferation by ERK1/2 Pathway

In order to ascertain whether SCF/c-kit signaling modulates PASM cell proliferation by activating the ERK1/2 pathway, we next evaluated whether a selective ERK1/2 antagonist, FR180204 could suppress SCF-induced PASM cell proliferation. PASM cells were isolated from neonatal mice and exposed to varying doses of SCF. We first demonstrated that un-stimulated neonatal PASM cells do express c-kit (Figure 6A) and exposure of PASM cells to 100 ng/mL SCF not only increased the gene expression of c-kit (Figure 6A), but also caused an increase in p-ERK 1/2 expression (Figure 6B). These findings were accompanied by an increase in the percentage of Ki67pos PASM cells (13.4 ± 3 vs. 50 ± 12%; SCF 0 ng/ml vs SCF 100 ng/ml; p <0.02), (Figures 6C and 6D). Confirmatory findings with a BrdU Colorimetric Assay also demonstrated that PASM cells which were pre-treated with vehicle and subsequently exposed to SCF 100 ng/ml had increased BrdU incorporation as compared to vehicle alone (Figure 6E). In contrast, SCF- exposed PASM cells which were pre-treated with the ERK1/2 antagonist had suppressed BrdU incorporation (Figure 6E). Together, this suggests that SCF/c-kit signaling may modulate PASM cell proliferation by regulating the ERK1/2 pathway.

Discussion

The present study provides novel insight into the role of SCF/c-kit signaling in the pathogenesis of chronic hypoxia-induced pulmonary vascular remodeling. We show that the
expression of SCF and c-kit are increased in the pulmonary arteries of neonatal mice with PH and furthermore that neonatal mice with defective c-kit signaling have decreased chronic hypoxia-induced pulmonary vascular remodeling and proliferation. In addition, we demonstrate that inhibition of SCF/c-kit signaling attenuates neonatal chronic hypoxia-induced pulmonary vascular remodeling and decreases activation of the ERK1/2 pathway in PASM cells. Taken together, our present data not only demonstrates a mechanism by which SCF/c-kit signaling participates in chronic hypoxia-induced pulmonary vascular remodeling but it also provides a foundation to generate new therapies.

Prior investigators have demonstrated the presence of c-kit positive cells in remodeled pulmonary arterioles of animals and humans with PH. Davie et al demonstrated increased c-kit$^{pos}$ cells in the vasa vasorum of the pulmonary artery adventitia of hypoxic calves and suggested that c-kit$^{pos}$ cells in the vasa vasorum may contribute to pulmonary vascular remodeling by augmenting pulmonary artery adventitia neovascularization (9). Additionally, Frid et al demonstrated the presence of c-kit$^{pos}$ cells in the pulmonary artery media of hypoxic calves and showed that these cells had highly augmented proliferative, migratory, invasive, and mitogenic capabilities (19). In our study, we demonstrate c-kit positive cells in the endothelium, media and adventitia of remodeled pulmonary vessels and Western blot analysis of protein homogenates obtained from pulmonary arterioles demonstrated increased phosphorylated c-kit and SCF expression. This present finding is in keeping with prior data which demonstrated that hypoxia-inducible factor directly enhances the transcriptional activity of SCF and c-kit in response to hypoxia in tumor cell lines (20).

This hypoxia-induced enhanced c-kit and SCF expression is important in promoting angiogenesis following organ injury (21) and augmentation of SCF/c-kit signaling has been shown to improve organ repair by increasing angiogenesis (22). Interestingly, we did not find a significant effect of SCF/c-kit signaling on pulmonary angiogenesis during hypoxia-induced PH. We however speculate that the increased c-kit expression noted in the pulmonary arteries of neonatal mice with chronic hypoxia-induced PH was an adaptive effect to increase perfusion to the pulmonary vascular wall and this response may have become maladaptive and promoted pulmonary vascular cell proliferation and remodeling. This is consistent with data published by Wang et al, who demonstrated significant SCF-induced proliferation of aortic vascular smooth muscle cells (15) and decreased proliferation of aortic smooth muscle cells following femoral artery wire injury in c-kit and stem cell factor mutant mice.

In our present study, we also show that abrogation of SCF/c-kit signaling decreased pulmonary vascular cell proliferation and this was accompanied by decreased activation of the ERK1/2 pathway. This is intriguing as p42/p44 ERK, a member of the mitogen-activated protein kinase (MAPK) super family, has been previously shown to be up-regulated in hypoxic lungs and to mediate pulmonary vascular cell proliferation (18). Surprisingly, further questioning to elucidate the cellular population which had increased ERK1/2 activation revealed that isolated neonatal PASM cells express c-kit and they increased their proliferation and ERK1/2 activation following SCF stimulation. This was unexpected as other studies have not demonstrated c-kit expression on PASM cells, but rather their expression on native pulmonary vasculature cells was mainly restricted to endothelial
It is possible that the variability in c-kit expression may be due to differences in the species studied as well as the developmental stage at the time of evaluation. Nonetheless, our finding is consistent with those of Davis et al who also showed that c-kit is expressed on adult PASM cells (24).

Finally, it is important to mention the limitations of this study. c-kit is present on several lung cells and thus its effects may not be localized to the pulmonary vascular bed. Indeed, studies in our laboratory have revealed an important role for c-kit in lung angiogenesis and alveolarization. Unexpectedly, in this present study, ACK2 treated hypoxic mice not only had an improvement in PH but they had better alveolar structure as compared to hypoxia PL-mice. Further studies will however be needed to delineate dose and temporal related effects as there was a trend towards a decrease in lung alveolarization and angiogenesis in the normoxic ACK2 treated mice. In addition, whilst the attenuation in pulmonary vascular remodeling evidenced following inhibition of SCF/c-kit signaling maybe potentially due to decreased ERK1/2 activation, we recognize that some of the PASM cells utilized in our in vitro studies may have been obtained from conduit vessels and their exact role in PH is unclear. We also acknowledge that some populations of c-kit positive cells in the pulmonary vasculature are progenitor cells and these cells may potentiate vascular remodeling by either differentiating into myofibroblasts or secreting mitogenic factors. It is also possible that the reduction in RVH evidenced following c-kit antagonism was not entirely due to the improvement in PH but rather a direct effect of c-kit on myocardial mitogenesis.

Our present study however provides distinct and new evidence of the mechanistic role of SCF/c-kit signaling in the pathogenesis of chronic hypoxia-induced pulmonary vascular remodeling. We demonstrate in vivo and in vitro the functional relevance of SCF/c-kit signaling in PH and we show that activation of SCF/c-kit signaling potentiates pulmonary artery smooth muscle cell proliferation and this is accompanied by ERK1/2 activation. We therefore speculate that future investigations evaluating novel strategies to inhibit SCF/c-kit receptor signaling may provide innovative therapies to attenuate chronic hypoxia-induced pulmonary vascular remodeling.

Methods

Materials

Pregnant FVB/NJ mice, WBB6F1- Kit W− v/+ were obtained from Jackson Laboratories (Bal Harbor, ME). Primary antibodies utilized were: c-kit (1:50, DAKO Carpinteria, CA), SCF (1:500; Abcam, Cambridge, MA), α-Smooth Muscle Actin (α-sma: 1:500, Sigma-Aldrich; St. Louis, MO), von Willebrand factor (vWF: 1:200; DAKO), and Ki67 (1:100; Abcam). Secondary antibodies utilized were: Biotinylated anti-mouse IgG (1:200, Vector, CA), HRP Conjugated Donkey Anti-Goat IgG (1:2000, Jackson Immunoresearch, PA), Goat Anti-Mouse IgG Alkaline Phosphatase (1:100, Sigma-Aldrich), and Goat Anti-Rabbit IgG-Peroxidase (1:100, Sigma-Aldrich). Mouse c-kit neutralizing antibody (ACK2; 50μg/kg) and recombinant SCF were both obtained from EBioscience (San Diego, CA). FR180204 (a selective ERK1/2 antagonist) was obtained from Santa Cruz Biotechnology (Santa Cruz, CA).
Animal Care and Treatment

All animal experiments were performed according to guidelines set forth by the University of Miami Miller School of Medicine Animal Care and Use Committee. In the first set of studies, neonatal c-kit mutant mice (WBB6F1- Kit<sup>W−/+</sup>) as well as their wild-type controls (n=22/group) were exposed to normobaric hypoxia (FiO<sub>2</sub>=0.12) or normoxia (RA; FiO<sub>2</sub>=0.21) for 2 wk. In the second set of studies, FVB/NJ neonatal mice (1–2 d old; n=26) were exposed to normobaric hypoxia (FiO<sub>2</sub>=0.12) or normoxia (RA; FiO<sub>2</sub>=0.21) for two wk. After one week of this exposure, the mice were randomly assigned to receive daily intraperitoneal (IP) injections of normal saline (Placebo (PL); n=15), or anti-c-kit antibody (ACK2; 50μg/kg; n=11) for seven days, from postnatal day 7–14. The dose and frequency of dosing was based on a prior study (25). The FiO<sub>2</sub> utilized in this neonatal study was based on previous studies which demonstrated increased mortality of the mice if lower FiO<sub>2</sub> or a longer duration of exposure were utilized (26).

Assessment of PH

Right ventricular systolic pressure (RVSP) was measured and continuously recorded on a Gould polygraph (model TA-400, Gould instruments, Cleveland, Ohio) as previously described with minor modifications (27). RVH was assessed by measuring the RV/LV +S.

Lung Morphometric Analysis

Lung perfusion was performed as previously described (28). Serial paraffin-embedded lung sections five micrometer (μm) thick were stained with antibodies against α-sma (clone 1A4, Sigma-Aldrich) and vWF (DAKO). The medial wall thickness of fully muscular intra-acinar pulmonary vessels was determined using the formula: 2 MT X 100/ED where MT is the distance between internal and external elastic laminae and ED is the external diameter. Approximately 35–40 arteries were evaluated per slide and all morphometric analyses were performed by a blinded observer. The number of proliferating pulmonary vascular cells was determined by staining lung sections with Ki67, a marker of cell proliferation. The proliferation index (PI) was calculated by the following formula: (No. of Ki67<sup>pos</sup> cells / No. of Ki67<sup>pos</sup> + No. of Ki67<sup>neg</sup> cells per pulmonary vessel). Alveolarization was determined by measuring the mean linear intercept (MLI) as previously described (29). Images from five randomly selected, non-overlapping parenchymal fields were acquired from lung sections of each animal (n=5/group) at 20 X magnification. Lung vascular density was determined by counting the number of vWF positive (vWF<sup>pos</sup>) blood vessels/high power field, (20–50 μm in diameter). Five randomly selected, non-overlapping parenchymal fields were evaluated from lung sections of each animal (n=5/group) by a blinded observer.

Pulmonary Artery Smooth Muscle (PASM) Cell Culture

The segmental and sub-segmental branches of the right and left pulmonary arteries (3rd–4th generation) were dissected free of surrounding tissue. The arteries were then minced, washed with PBS and digested with collagenase. Digested arteries were incubated in DMEM/F12 supplemented with penicillin (100 u/ml), streptomycin (10 ug/ml) and 10% fetal bovine serum (FBS) until cell proliferation was evident. PASM cells were identified by their characteristic hill-and-valley morphology and >99% positive immunostaining for
calponin and α-smooth muscle actin. This was taken as evidence that cultures were not contaminated with fibroblasts or endothelial cells. PASM cells (passages 2–4) were seeded on 96 well plates (1x10^4 cells/well) and cultured for 24 hours in DMEM/F-12 containing 10% FBS. In order to render the cells quiescent, they were serum starved for 48 h with DMEM/F-12 containing 0.5% FBS. Cells were then exposed to the specific ERK1/2 antagonist, FR180204 40μM or DMSO (vehicle) for 1 hr followed by a 72h incubation period with SCF (0 and 100 ng/ml). The latter dose of SCF was chosen as pilot experiments in our laboratory revealed that lower doses of SCF had no effect on cell proliferation. All treatments were done in duplicate and all experiments were repeated four times.

**PASM Cell Proliferation**

PASM cell proliferation was determined by the BrdU Colorimetric ELISA assay according to the manufacturer instructions (Roche Applied Science, Indianapolis, IN).

**Real Time RT-PCR**

Total RNA was extracted from neonatal PASM cells following exposure to 0, 1, 10, and 100 ng/mL SCF as previously described (30). The gene expression of c-kit and Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was quantified by real time RT-PCR using Real-Time Gene Expression Assay (Applied Biosystems, Carlsbad, CA). The relative quantity of c-kit was normalized to GAPDH.

**Western Blot**

The protein expression of c-kit, SCF, ERK1/2, p-ERK1/2 and β-actin in pulmonary artery homogenates was determined by Western blot analysis as previously described (27). Band intensity was quantified with Quantity One software (Bio-Rad, CA).

**Immunohistochemistry and Immunofluorescence**

Paraffin-embedded lung sections were deparaffinized and rehydrated. Following antigen retrieval, endogenous peroxidase in the lung sections was blocked by incubating for 45 minutes with 0.3% H_2O_2 in methanol. Samples were washed and incubated for 1h at room temperature with 10% donkey serum to saturate any non-specific binding sites of the antibodies, followed by overnight incubation at 4°C with appropriate primary antibodies. After washing, the sections were incubated with the appropriate secondary antibodies at room temperature. Fluorescent signals were enhanced by using a tyramide signal amplification kit (Perkin Elmer, Waltham, MA) according to manufacturers’ instructions and sections were evaluated under a Zeiss Confocal Microscope (model LSM-510; Carl Zeiss Microimaging, Inc., Thornwood, NY).

**Statistics**

All results are reported as mean ± SD. Data were analyzed by ANOVA followed by a post-hoc analysis (Holm-Sidak). Values of p<0.05 were considered statistically significant. Statistical analysis was performed using SigmaStat software (SyStat Software Inc., San Jose, CA).
Acknowledgments

Supported by: National Institute of Health Career Development Award (Bethesda, MD, USA) to KY and Batchelor Research Foundation Award (Miami, FL, USA) to KY and University of Miami Project New Born.

References

1. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling: Cellular and molecular mechanisms. Circ Res. 2006; 99:675–691. [PubMed: 17008597]

2. Bernex F, De Sepulveda P, Kress C, Elbaz C, Delouis C, Panthier JJ. Spatial and temporal patterns of c-kit-expressing cells in wla/c+ and wla/c/wla/c mouse embryos. Development. 1996; 122:3023–3033. [PubMed: 8898216]

3. Ashman LK, Cambureri AC, To LB, Levinsky RJ, Juttner CA. Expression of the yb5. B8 antigen (c-kit proto-oncogene product) in normal human bone marrow. Blood. 1991; 78:30–37. [PubMed: 1712644]

4. Papayannopoulou T, Brice M, Broudys VC, Zsebo KM. Isolation of c-kit receptor-expressing cells from bone marrow, peripheral blood, and fetal liver: Functional properties and composite antigenic profile. Blood. 1991; 78:1403–1412. [PubMed: 1715789]

5. Hollenbeck ST, Sakakibara K, Faries PL, Workhu B, Liu B, Kent KC. Stem cell factor and c-kit are expressed by and may affect vascular smcs through an autocrine pathway. J Surg Res. 2004; 120:288–294. [PubMed: 15234225]

6. Besmer P. The kit ligand encoded at the murine steel locus: A pleiotropic growth and differentiation factor. Curr Opin Cell Biol. 1991; 3:939–946. [PubMed: 1726043]

7. Reber L, Da Silva CA, Frossard N. Stem cell factor and its receptor c-kit as targets for inflammatory diseases. Eur J Pharmacol. 2006; 533:327–340. [PubMed: 16483568]

8. Lammie A, Drobnjak M, Gerald W, Saad A, Cote R, Cordon-Cardo C. Expression of c-kit and c-kit ligand proteins in normal human tissues. J Histochem Cytochem. 1994; 42:1417–1425. [PubMed: 7523489]

9. Davie NJ, Crosso JT, Frid MG, et al. Hypoxia-induced pulmonary artery adventitial remodeling and neovascularization: Contribution of progenitor cells. Am J Physiol Lung Cell Mol Physiol. 2004; 286:L668–678. [PubMed: 12754186]

10. Crosso JT Jr, Garat CV, Reusch JEB, et al. Rosiglitazone attenuates hypoxia-induced pulmonary arterial remodeling. Am J Physiol Lung Cell Mol Physiol. 2007; 292:L885–897. [PubMed: 17189321]

11. Montani D, Perros F, Gambaryan N, et al. C-kit–positive cells accumulate in remodeled vessels of idiopathic pulmonary arterial hypertension. Am J Resp Crit Care Med. 2011; 184:116–123. [PubMed: 21471108]

12. Ashman LK. The biology of stem cell factor and its receptor c-kit. Int J Biochem Cell Biol. 1999; 31:1037–1051. [PubMed: 10582338]

13. Matsui J, Wakabayashi T, Asada M, Yoshimatsu K, Okada M. Stem cell factor/c-kit signaling promotes the survival, migration, and capillary tube formation of human umbilical vein endothelial cells. J Biol Chem. 2004; 279:18600–18607. [PubMed: 14985355]

14. Wang CH, Anderson N, Li SH, et al. Stem cell factor deficiency is vasculoprotective: Unraveling a new therapeutic potential of imatinib mesylate. Circ Res. 2006; 99:617–625. [PubMed: 16931795]

15. Wang CH, Verma S, Hsieh IC, et al. Stem cell factor attenuates vascular smooth muscle apoptosis and increases intimal hyperplasia after vascular injury. Arterioscler Thromb Vasc Biol. 2007; 27:540–547. [PubMed: 17204664]

16. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med. 2005; 353:1412–1413. [PubMed: 16192491]

17. Jin N, Hatton N, Swartz DR, et al. Hypoxia activates jun-n-terminal kinase, extracellular signal-regulated protein kinase, and p38 kinase in pulmonary arteries. Am J Respir Cell Mol Biol. 2000; 23:593–601. [PubMed: 11062137]

18. Das M, Bouchez DM, Moore MJ, Hopkins DC, Nemenoff RA, Stenmark KR. Hypoxia-induced proliferative response of vascular adventitial fibroblasts is dependent on g protein-mediated
activation of mitogen-activated protein kinases. J Biol Chem. 2001; 276:15631–15640. [PubMed: 11278727]

19. Frid MG, Li M, Gnanasekharan M, et al. Sustained hypoxia leads to the emergence of cells with enhanced growth, migratory, and promitogenic potentials within the distal pulmonary artery wall. Am J Physiol Lung Cell Mol Physiol. 2009; 297:L1059–1072. [PubMed: 19767409]

20. Han Z-B, Ren H, Zhao H, et al. Hypoxia-inducible factor (hif)-1α directly enhances the transcriptional activity of stem cell factor (scf) in response to hypoxia and epidermal growth factor (egf). Carcinogenesis. 2008; 29:1853–1861. [PubMed: 18339685]

21. Sun L, Lee J, Fine HA. Neuronally expressed stem cell factor induces neural stem cell migration to areas of brain injury. J Clin Invest. 2004; 113:1364–1374. [PubMed: 15124028]

22. Xiang FL, Lu X, Hammoud L, et al. Cardiomyocyte-specific overexpression of human stem cell factor improves cardiac function and survival after myocardial infarction in mice. Circulation. 2009; 120:1065–1074. [PubMed: 19738140]

23. Suzuki T, Suzuki S, Fujino N, et al. C-kit immunoexpression delineates a putative endothelial progenitor cell population in developing human lungs. Am J Physiol Lung Cell Mol Physiol. 2014; 306(9):L855–L865. [PubMed: 24583878]

24. Davis BN, Hilyard AC, Nguyen PH, Lagna G, Hata A. Induction of microRNA-221 by platelet-derived growth factor signaling is critical for modulation of vascular smooth muscle phenotype. J Biol Chem. 2009; 284:3728–3738. [PubMed: 19088079]

25. Okura M, Maeda H, Nishikawa S-i, Mizoguchi M. Effects of monoclonal anti-c-kit antibody (ACK2) on melanocytes in newborn mice. J Investig Dermatol. 1995; 105:322–328. [PubMed: 7545201]

26. Ambalavanan N, Bulger A, Murphy-Ullrich J, Oparil S, Chen YF. Endothelin-A receptor blockade prevents and partially reverses neonatal hypoxic pulmonary vascular remodeling. Pediatr Res. 2005; 57:631–636. [PubMed: 1574824]

27. Young KC, Torres E, Hatziagrigg KE, Hehre D, Suguihara C, Hare JM. Inhibition of the SDF-1/CXCR4 axis attenuates neonatal hypoxia-induced pulmonary hypertension. Circ Res. 2009; 104:1293–1301. [PubMed: 19423843]

28. Bellodi C, Lidonnici MR, Hamilton A, et al. Targeting autophagy potentiates tyrosine kinase inhibitor-induced cell death in Philadelphia chromosome-positive cells, including primary cml stem cells. J Clin Invest. 2009; 119:1109–1123. [PubMed: 19363292]

29. Miranda LF, Rodrigues CO, Ramachandran S, et al. Stem cell factor improves lung recovery in rats following neonatal hypoxia-induced lung injury. Pediatr Res. 2013; 74:682–688. [PubMed: 24153399]

30. Wu S, Peng J, Duncan MR, Kasismayajula K, Grotendorst G, Bancalari E. Alk-5 mediates endogenous and TGF-Beta1-induced expression of connective tissue growth factor in embryonic lung. Am J Respir Cell Mol Biol. 2007; 36:552–561. [PubMed: 17197570]
Figure 1. Stem cell factor (SCF) and c-kit expression in the pulmonary arterioles of mice with chronic hypoxia-induced pulmonary hypertension (PH)

A. Increased c-kit protein expression in the pulmonary arterioles of neonatal mice exposed to 14 days of hypoxia, (*p < 0.03, Room Air versus vs. hypoxia; n = 5/group). c-kit expression is normalized to β-actin.

B. Increased SCF protein expression in the pulmonary arterioles of neonatal mice exposed to 14 days of hypoxia, (*p < 0.001, Room Air versus vs. hypoxia; n = 5/group). SCF expression is normalized to β-actin.

C. Increased phosphorylated c-kit protein expression in the pulmonary arterioles of neonatal mice exposed to 14 days of hypoxia, (*p < 0.002, Room Air versus vs. hypoxia; n = 5/group). Phosphorylated c-kit expression is normalized to β-actin.

D. Lung sections stained with α-smooth muscle actin (green) and c-kit antibodies (red) demonstrating c-kit positive cells in the endothelium, media (yellow staining) and adventitia of the remodeled pulmonary vessel. Original magnification x 400. Scale bar is 25μm.
Figure 2. c-kit neutralizing antibody (ACK2) attenuates neonatal chronic hypoxia-induced PH
A. Decreased RSVP (right ventricular systolic pressure) in chronic hypoxic mice which received ACK2, (* p<0.0001: Room air vs. hypoxia-PL, ** p<0.02: hypoxia-PL vs. hypoxia-ACK2; n=8–10/group). White bars are room air (RA) and hatched bars are hypoxia.
B. Decreased right ventricular hypertrophy (RVH) in hypoxic-ACK2 mice (* p<0.001: RA vs hypoxia-PL, ** p<0.01: hypoxia-PL vs hypoxia-ACK2; n=6–8/group).
C. Decreased α-smooth muscle actin (red) staining in the pulmonary vessels of ACK2 treated hypoxic mice. Original magnification x 400.
D. Morphometric analysis performed on 35–40 (20–50 μm diameter) pulmonary vessels (n=5/group) demonstrated that ACK2 attenuated chronic hypoxia-induced pulmonary vascular remodeling (* p< 0.05: RA vs hypoxia-PL, ** p<0.05: hypoxia-PL vs. hypoxia-ACK2).
E. Pulmonary vessels stained with anti-Ki67 antibody (red) and DAPI (blue). Ki67^{pos} cells (pink) were more abundantly present in the pulmonary vessels of hypoxia-PL mice as compared to hypoxia-ACK2 treated. Original magnification x 400.
F. Decreased percentage of Ki67^{pos} cells in pulmonary vessels of hypoxic ACK2 treated mice. (* p< 0.05: RA vs. hypoxia-PL; ** p<0.04: hypoxia-PL vs hypoxia-ACK2; n=5/group).
Figure 3. Effect of c-kit neutralizing antibody (ACK2) on lung alveolarization and angiogenesis

A. H&E stained lung sections demonstrating improved alveolar structure in hypoxia-exposed mice treated with ACK2. Original magnification x 200. Scale bar 50 μm.

B. Decreased mean linear intercept (MLI) in hypoxic-ACK2 mice (* p< 0.003: RA-PL vs. hypoxia-PL, **p < 0.03: hypoxia-PL vs. hypoxia-ACK2; n = 5/group). White bars are RA and hatched bars are hypoxia.

C. No difference in vascular density between hypoxic-groups (* p< 0.005: RA vs. hypoxia-PL or hypoxia-ACK2).
Figure 4. Neonatal c-kit mutant mice have decreased PH
A. Lower RSVP in hypoxic neonatal c-kit mutant mice compared to control hypoxic mice, (*p<0.001: Room air control vs. hypoxia control; ** p <0.01: hypoxia control vs. hypoxia mutant, n=10/group). White bars are room air (RA) and hatched bars are hypoxia.
B. Less RVH in hypoxic neonatal c-kit mutant mice compared to control hypoxic mice, (*p<0.001: RA control vs. hypoxia control; ** p <0.005: hypoxia control vs. hypoxia mutant, n=10/group).
C. Lung sections stained with α-smooth muscle actin (red) demonstrating decreased pulmonary vascular muscularization in the chronically hypoxic c-kit mutant mice as compared to the control hypoxic mice. Original magnification x 400. Scale bar is 25 μm.

D. Chronically hypoxic c-kit mutant mice had decreased medial wall thickness as compared to control hypoxic mice, (*p<0.001: RA control vs. hypoxia control; ** p <0.01: hypoxia control vs. hypoxia mutant, n=5/group).

E. Pulmonary vessels stained with anti-Ki67 antibody (red) and DAPI (blue). Ki67pos cells (pink) were more abundantly present in the pulmonary vessels of control hypoxic mice as compared to hypoxic c-kit mutant mice. Original magnification x 400. Scale bar is 25 μm.

F. Increased percentage of Ki67pos cells in the pulmonary vessels of control hypoxic mice as compared to hypoxic c-kit mutant mice, (*p<0.001: RA control vs. hypoxia control; ** p <0.03: hypoxia control vs. hypoxia mutant, n=5/group)
Figure 5. c-kit regulates ERK1/2 activation
A. Increased lung p-ERK1/2 activation in hypoxic control mice as compared of c-kit mutant mice, (*p<0.001: RA control vs. hypoxia control; ** p<0.02: hypoxia control vs. hypoxia mutant n=5/group). White bars are room air (RA) and hatched bars are hypoxia. p-ERK1/2 and T-ERK1/2 expression are normalized to β-actin.
B. Hypoxic-ACK2 mice had decreased lung p-ERK1/2 activation as compared to hypoxic-PL mice (* p<0.001: RA-PL vs hypoxia-PL; ** p<0.003: hypoxia-PL vs hypoxia-ACK2; n=5/group).
Figure 6. SCF stimulates pulmonary artery smooth muscle (PASM) cell proliferation

A. c-kit mRNA expression in neonatal PASM cells exposed to varying doses of SCF. c-kit transcripts were detected in un-stimulated neonatal PASM cells and these transcripts increased following exposure to SCF 100 ng/mL (* p< 0.03: 0 ng/mL SCF vs 100 ng/mL SCF; n=4/group).

B. Increased p-ERK1/2 activation in PASM exposed to SCF 100 ng/ml (*p<0.04: SCF 0 ng/ml vs. SCF 100 ng/ml; n=4/group). p-ERK1/2 and T-ERK1/2 expression are normalized to β-actin.

C. Ki67pos (pink) cells in untreated PASM cells (left panel) and cells exposed to SCF 100 ng/ml (right panel). Original magnification x 400. Scale bar is 50μm.

D. Increased percentage of Ki67pos cells in neonatal PASM cells exposed to SCF 100 ng/ml (* p< 0.05; 0 ng/mL SCF vs 100 ng/mL SCF; n=4/group).

E. Neonatal PASM cells which were pre-treated with vehicle and exposed to SCF 100 ng/ml had increased BrdU incorporation, (* p<0.007; DMSO vs DMSO+ SCF 100 ng/ml). Exposure of PASM to FR180204 alone suppressed BrdU incorporation (** p<0.001; DMSO + SCF 100 ng/ml vs FR180204). SCF- exposed PASM cells which were pre-treated with the ERK1/2 antagonist had suppressed BrdU incorporation († p<0.002; DMSO+ SCF 100 ng/ml vs FR180204 + SCF 100 ng/ml).